Successful withdrawal of omalizumab in a patient with severe asthma: Free IgE as a possible biomonitor

Christian Domingo; X. Pomares; M. J. Amengual; M. Ollert

doi:10.1177/1721727X1401200217

Successful withdrawal of omalizumab in a patient with severe asthma: Free IgE as a possible biomonitor

Christian Domingo^*, X. Pomares, M. J. Amengual, M. Ollert

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Abstract

To date, the pharmacological activity and clinical benefits of omalizumab have been well described, however several questions still remain unanswered, such as the moment to withdraw the drug as well as the possible biological markers that may be useful to do so. In the present case report, we describe our experience with our dose-reduction protocol in a middle-aged patient and elucidate the usefulness of free IgE levels.

Original language	English
Pages (from-to)	389-393
Number of pages	5
Journal	European Journal of Inflammation
Volume	12
Issue number	2
DOIs	https://doi.org/10.1177/1721727X1401200217
Publication status	Published - May 2014
Externally published	Yes

Keywords

Biomonitoring
Dose decrease
Free IgE
Omalizumab withdrawal

Access to Document

10.1177/1721727X1401200217

Cite this

@article{f59e300ed3ef40a0ac48a291e372bc24,

title = "Successful withdrawal of omalizumab in a patient with severe asthma: Free IgE as a possible biomonitor",

abstract = "To date, the pharmacological activity and clinical benefits of omalizumab have been well described, however several questions still remain unanswered, such as the moment to withdraw the drug as well as the possible biological markers that may be useful to do so. In the present case report, we describe our experience with our dose-reduction protocol in a middle-aged patient and elucidate the usefulness of free IgE levels.",

keywords = "Biomonitoring, Dose decrease, Free IgE, Omalizumab withdrawal",

author = "Christian Domingo and X. Pomares and Amengual, {M. J.} and M. Ollert",

year = "2014",

month = may,

doi = "10.1177/1721727X1401200217",

language = "English",

volume = "12",

pages = "389--393",

journal = "European Journal of Inflammation",

issn = "1721-727X",

publisher = "SAGE Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Successful withdrawal of omalizumab in a patient with severe asthma

T2 - Free IgE as a possible biomonitor

AU - Domingo, Christian

AU - Pomares, X.

AU - Amengual, M. J.

AU - Ollert, M.

PY - 2014/5

Y1 - 2014/5

N2 - To date, the pharmacological activity and clinical benefits of omalizumab have been well described, however several questions still remain unanswered, such as the moment to withdraw the drug as well as the possible biological markers that may be useful to do so. In the present case report, we describe our experience with our dose-reduction protocol in a middle-aged patient and elucidate the usefulness of free IgE levels.

AB - To date, the pharmacological activity and clinical benefits of omalizumab have been well described, however several questions still remain unanswered, such as the moment to withdraw the drug as well as the possible biological markers that may be useful to do so. In the present case report, we describe our experience with our dose-reduction protocol in a middle-aged patient and elucidate the usefulness of free IgE levels.

KW - Biomonitoring

KW - Dose decrease

KW - Free IgE

KW - Omalizumab withdrawal

UR - http://www.scopus.com/inward/record.url?scp=84905868832&partnerID=8YFLogxK

U2 - 10.1177/1721727X1401200217

DO - 10.1177/1721727X1401200217

M3 - Article

AN - SCOPUS:84905868832

SN - 1721-727X

VL - 12

SP - 389

EP - 393

JO - European Journal of Inflammation

JF - European Journal of Inflammation

IS - 2

ER -

Successful withdrawal of omalizumab in a patient with severe asthma: Free IgE as a possible biomonitor

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this